Class 2 Medicines Recall: Novartis Pharmaceuticals UK, Sandimmun Oral Solution, EL(22)A/40

Novartis Pharmaceuticals UK are recalling a batch of Sandimmun Oral Solution due to the presence of crystals in the solution.

MDR Number: MDR 050-09/22

Company name: Novartis Pharmaceuticals UK

Product description: Sandimmun Oral Solution PL 00101/0124

Details of the affected batch:

Brief description of problem:

Novartis Pharmaceuticals UK are recalling the above batch due to the presence of crystals in the solution. The crystals have been identified as the active substance (ciclosporin). The presence of crystals has been observed in some finished product packs marketed in other countries that share the same master batch as the UK batch above. Therefore, this UK batch is recalled as a precautionary measure. Novartis Pharmaceuticals UK have confirmed no other batches of the product are impacted.

Advice to Healthcare Professionals:

Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.

Advice to Patients:

• Patients should not stop taking Sandimmun Oral Solution without speaking to your doctor or other healthcare professionals, as stopping your treatment may increase the risk of your transplanted organ being rejected.
• The Marketing Authorisation Holder in the UK has not received any product complaints or adverse reactions related to the issue above. However, if you feel unwell whilst taking medicines from this batch then please seek urgent medical attention. Adverse reactions should also be reported via the MHRA Yellow Card scheme.
• If you have any questions about your Sandimmun Oral Solution or observe crystallised particles in the solution, talk to your pharmacist, transplant team or other healthcare professionals for advice.

Company contacts for further information:

For more information, medical or supply enquiries, please contact 01276 698370, or email medinfo.uk@novartis.com

Full recall